Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Dec;62(6):891–896. doi: 10.1038/bjc.1990.404

A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats.

A Marinelli 1, C J van de Velde 1, P J Kuppen 1, H C Franken 1, J H Souverijn 1, A M Eggermont 1
PMCID: PMC1971565  PMID: 2124136

Abstract

Systemic toxicity is usually the dose-limiting factor in cancer chemotherapy. Regional chemotherapy is therefore an attractive strategy in the treatment of liver metastasis. Two ways of regional chemotherapy, hepatic artery infusion (HAI) and isolated liver perfusion (ILP), were compared investigating the difference in toxicity with tissue and biofluid concentrations of mitomycin C (MMC). In wistar derived WAG rats the maximally tolerated dose of mitomycin C via HAI was 1.2 mg kg-1. Body weight measurements after HAI with doses higher than 1.2 mg kg-1 suggest both an acute and delayed toxic effect of mitomycin C since the time weight curves were triphasic: a rapid weight loss, a steady state and a second fall in weight phase. These rats died due to systemic toxicity. ILP with 4.8 mg kg-1 was associated with no signs of systemic toxicity and only transient mild hepatotoxicity. ILP with 6.0 mg kg-1 was fatal mainly due to hepatic toxicity. The four times higher maximally tolerated dose in ILP resulted in a 4-5 times higher peak concentration of mitomycin C in liver tissue, while the plasma concentration remained significantly lower than in the HAI treated rats. In the tumour tissue a 500% higher concentration of mitomycin C was measured in the ILP with 4.8 mg kg-1 than in HAI with 1.2 mg kg-1 treated rats. We demonstrated that when mitomycin C was administered by ILP a 400% higher dose could be safely administered and resulted in a five times higher tumour tissue concentration. In view of the steep dose-response curve of this alkylating agent this opens new perspectives for the treatment of liver metastasis.

Full text

PDF
891

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman N. B. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery. 1974 Apr;75(4):589–596. [PubMed] [Google Scholar]
  2. Adson M. A. Hepatic metastases in perspective. AJR Am J Roentgenol. 1983 Apr;140(4):695–700. doi: 10.2214/ajr.140.4.695. [DOI] [PubMed] [Google Scholar]
  3. Adson M. A., van Heerden J. A., Adson M. H., Wagner J. S., Ilstrup D. M. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984 Jun;119(6):647–651. doi: 10.1001/archsurg.1984.01390180015003. [DOI] [PubMed] [Google Scholar]
  4. Aigner K., Walther H., Tonn J. C., Krahl M., Wenzl A., Merker G., Schwemmle K. Die isolierte Leberperfusion mit 5-Fluorouracil (5-FU) beim Menschen. Chirurg. 1982 Sep;53(9):571–573. [PubMed] [Google Scholar]
  5. August D. A., Sugarbaker P. H., Ottow R. T., Gianola F. J., Schneider P. D. Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg. 1985 Feb;201(2):210–218. doi: 10.1097/00000658-198502000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Balch C. M., Urist M. M., Soong S. J., McGregor M. A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg. 1983 Nov;198(5):567–573. doi: 10.1097/00000658-198311000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cattell V. Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat. Am J Pathol. 1985 Oct;121(1):88–95. [PMC free article] [PubMed] [Google Scholar]
  8. Chang A. Y., Kuebler J. P., Pandya K. J., Israel R. H., Marshall B. C., Tormey D. C. Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids. Cancer. 1986 Jun 15;57(12):2285–2290. doi: 10.1002/1097-0142(19860615)57:12<2285::aid-cncr2820571209>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  9. Chen H. S., Gross J. F. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep. 1980 Jan;64(1):31–40. [PubMed] [Google Scholar]
  10. Collins J. M. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984 May;2(5):498–504. doi: 10.1200/JCO.1984.2.5.498. [DOI] [PubMed] [Google Scholar]
  11. Crooke S. T., Bradner W. T. Mitomycin C: a review. Cancer Treat Rev. 1976 Sep;3(3):121–139. doi: 10.1016/s0305-7372(76)80019-9. [DOI] [PubMed] [Google Scholar]
  12. Doll D. C., Weiss R. B., Issell B. F. Mitomycin: ten years after approval for marketing. J Clin Oncol. 1985 Feb;3(2):276–286. doi: 10.1200/JCO.1985.3.2.276. [DOI] [PubMed] [Google Scholar]
  13. Foster J. H., Berman M. M. Solid liver tumors. Major Probl Clin Surg. 1977;22:1–342. [PubMed] [Google Scholar]
  14. Foster J. H., Lundy J. Liver Metastases. Curr Probl Surg. 1981 Mar;18(3):157–202. doi: 10.1016/s0011-3840(81)80009-3. [DOI] [PubMed] [Google Scholar]
  15. Ganz P. A., Gold B. S., Tandron I., Lurie K. Angina pectoris after doxorubicin and mitomycin therapy. Cancer Treat Rep. 1983 Jan;67(1):98–99. [PubMed] [Google Scholar]
  16. Gunstream S. R., Seidenfeld J. J., Sobonya R. E., McMahon L. J. Mitomycin-associated lung disease. Cancer Treat Rep. 1983 Mar;67(3):301–304. [PubMed] [Google Scholar]
  17. IYER V. N., SZYBALSKI W. MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA. Science. 1964 Jul 3;145(3627):55–58. doi: 10.1126/science.145.3627.55. [DOI] [PubMed] [Google Scholar]
  18. Iwatsuki S., Esquivel C. O., Gordon R. D., Starzl T. E. Liver resection for metastatic colorectal cancer. Surgery. 1986 Oct;100(4):804–810. [PMC free article] [PubMed] [Google Scholar]
  19. Izumi B., Tashiro S., Miyauchi Y. Anticancer effects of local administration of mitomycin C via the hepatic artery or portal vein on implantation and growth of VX2 cancer injected into rabbit liver. Cancer Res. 1986 Aug;46(8):4167–4170. [PubMed] [Google Scholar]
  20. Kerpel-Fronius S., Verwey J., Stuurman M., Kanyár B., Lelieveld P., Pinedo H. M. Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism. Cancer Chemother Pharmacol. 1988;22(2):104–108. doi: 10.1007/BF00257305. [DOI] [PubMed] [Google Scholar]
  21. Kuppen P. J., Schuitemaker H., van 't Veer L. J., de Bruijn E. A., van Oosterom A. T., Schrier P. I. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res. 1988 Jun 15;48(12):3355–3359. [PubMed] [Google Scholar]
  22. Lazarus H. M., Gottfried M. R., Herzig R. H., Phillips G. L., Weiner R. S., Sarna G. P., Fay J., Wolff S. N., Sudilovsky O., Gale R. P. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer. 1982 May 1;49(9):1789–1795. doi: 10.1002/1097-0142(19820501)49:9<1789::aid-cncr2820490910>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  23. Marquet R. L., Westbroek D. L., Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer. 1984 May 15;33(5):689–692. doi: 10.1002/ijc.2910330521. [DOI] [PubMed] [Google Scholar]
  24. Moertel C. G. Chemotherapy of gastrointestinal cancer. N Engl J Med. 1978 Nov 9;299(19):1049–1052. doi: 10.1056/NEJM197811092991906. [DOI] [PubMed] [Google Scholar]
  25. Schneider A., Kemeny N., Chapman D., Niedzwiecki D., Oderman P. Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. Cancer. 1989 Dec 1;64(11):2203–2206. doi: 10.1002/1097-0142(19891201)64:11<2203::aid-cncr2820641103>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  26. Schwemmle K., Link K. H., Rieck B. Rationale and indications for perfusion in liver tumors: current data. World J Surg. 1987 Aug;11(4):534–540. doi: 10.1007/BF01655820. [DOI] [PubMed] [Google Scholar]
  27. Sigurdson E. R., Ridge J. A., Kemeny N., Daly J. M. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 1987 Nov;5(11):1836–1840. doi: 10.1200/JCO.1987.5.11.1836. [DOI] [PubMed] [Google Scholar]
  28. Skibba J. L., Almagro U. A., Condon R. E., Petroff R. J., Jr A technique for isolation perfusion of the canine liver with survival. J Surg Res. 1983 Feb;34(2):123–132. doi: 10.1016/0022-4804(83)90051-3. [DOI] [PubMed] [Google Scholar]
  29. Slee P. H., de Bruijn E. A., Leeflang P., Kuppen P. J., van den Berg L., van Oosterom A. T. Variations in exposure to mitomycin C in an in vitro colony-forming assay. Br J Cancer. 1986 Dec;54(6):951–955. doi: 10.1038/bjc.1986.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tjaden U. R., de Bruijn E. A., van der Hoeven R. A., Jol C., van der Greef J., Lingeman H. Automated analysis of mitomycin C in body fluids by high-performance liquid chromatography with on-line sample pre-treatment. J Chromatogr. 1987 Sep 4;420(1):53–62. doi: 10.1016/0378-4347(87)80154-8. [DOI] [PubMed] [Google Scholar]
  31. Verweij J., van der Burg M. E., Pinedo H. M. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol. 1987 Jan;8(1):33–41. doi: 10.1016/s0167-8140(87)80020-8. [DOI] [PubMed] [Google Scholar]
  32. Wallner K. E., Li G. C. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res. 1987 Jan 15;47(2):493–495. [PubMed] [Google Scholar]
  33. de Brauw L. M., van de Velde C. J., Tjaden U. R., de Bruijn E. A., Bell A. V., Hermans J., Zwaveling A. In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue. J Surg Res. 1988 Feb;44(2):137–145. doi: 10.1016/0022-4804(88)90041-8. [DOI] [PubMed] [Google Scholar]
  34. van de Velde C. J., Kothuis B. J., Barenbrug H. W., Jongejan N., Runia R. D., de Brauw L. M., Zwaveling A. A successful technique of in vivo isolated liver perfusion in pigs. J Surg Res. 1986 Dec;41(6):593–599. doi: 10.1016/0022-4804(86)90084-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES